/
/
Modellering Osteosarcoma bruker Li-Fraumeni syndrom pasient-avledede Induced Pluripotent stamceller
A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Department of Integrative Biology and Pharmacology, McGovern Medical School,The University of Texas Health Science Center at Houston, 2Graduate School of Biomedical Sciences,The University of Texas MD Anderson Cancer Center UTHealth, 3Department of Musculoskeletal Oncology,The First Affiliated Hospital of Sun Yat-sen University, 4Women’s Health Institute,Cleveland Clinic Foundation, 5Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases,The University of Texas Health Science Center at Houston, 6Center for Precision Health, School of Biomedical Informatics and School of Public Health,The University of Texas Health Science Center at Houston
Chapters
- 00:04Title
- 00:47Differentiation of Li-Fraumeni Syndrome (LFS) Patient-derived Induced Pluripotent Stem Cell (iPSC) to Mesenchymal Stem Cell (MSC) (Days 0 – 28)
- 02:19iPSC-derived MSC Maturation (Day 28 – 45) and Differentiation of LFS MSC to Osteoblasts (Day 0 – 24)
- 04:33Xenograft In Vivo Tumorigenesis Model Setup
- 06:39Results: Representative LFS MSC Differentiation
- 08:10Conclusion
Her presenterer vi en protokoll for generering av indusert pluripotent stamceller (iPSCs) fra Li-Fraumeni syndrom (AKU) pasienten avledede fibroblaster, differensiering av iPSCs via stamceller (MSCs) osteoblasts og modellering i vivo tumorigenesis bruker AKU pasient-avledede osteoblasts.
